# A Study to Evaluate the Safety, Antiviral Effect, and Pharmacokinetics of Celgosivir in Combination With Peginterferon Alfa-2b and Ribavirin in Treatment-Naïve Patients With Chronic Hepatitis C

> **NCT00332176** · PHASE2 · UNKNOWN · sponsor: **BioWest Therapeutics Inc** · enrollment: 50 (estimated)

## Conditions studied

- Chronic Hepatitis C

## Interventions

- **DRUG:** Celgosivir
- **DRUG:** Celgosivir
- **DRUG:** Peginterferon alfa 2b + ribavirin

## Key facts

- **NCT ID:** NCT00332176
- **Lead sponsor:** BioWest Therapeutics Inc
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** UNKNOWN
- **Start date:** 2006-06
- **Primary completion:** 2008-12
- **Final completion:** 2008-12
- **Target enrollment:** 50 (ESTIMATED)
- **Last updated:** 2008-04-08


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00332176

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00332176, "A Study to Evaluate the Safety, Antiviral Effect, and Pharmacokinetics of Celgosivir in Combination With Peginterferon Alfa-2b and Ribavirin in Treatment-Naïve Patients With Chronic Hepatitis C". Retrieved via AI Analytics 2026-06-09 from https://api.ai-analytics.org/clinical/NCT00332176. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*